Salbutamol/ipratropium bromide

Generic name
Salbutamol/ipratropium bromide
Brand name
ATC Code
R03AL02
Compare …

Salbutamol/ipratropium bromide

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Acute asthma attack
  • Inhalation
    • < 5 years

      • (where SpO2 ≤ 94%): 2.5 mg/dose once only combined with ipratropium bromide at 0.25 mg/dose

        • If the child is badly out of breath, nebulization should continue as frequently as necessary with salbutamol and (at least) twice with ipratropium bromide for the initial inhalations.
        • After 1 to 2 times inhaling with insufficient effect: start low-threshold prednisone
    • ≥ 5 years

      • (where SpO2 ≤ 94%):  5 mg/dose once only combined with ipratropium bromide at 0.5 mg/dose

        • If the child is badly out of breath, nebulization should continue as frequently as necessary with salbutamol and (at least) twice with ipratropium bromide for the initial inhalations.
        • After 1 to 2 times inhaling with insufficient effect: start low-threshold prednisone
Removing reversible respiratory tract obstruction
  • Inhalation
    • Solution for nebulization
      • 12 years up to 18 years

        • 1 vial (0.5 mg ipratropium bromide and 2.5 mg salbutamol) 3-4x daily

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ADRENERGICS, INHALANTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Alpha- and beta-adrenoreceptor agonists
R03AA01
Selective beta-2-adrenoreceptor agonists
R03AC13
R03AC02
R03AC12
R03AC03
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
R03AK08
R03AK11
R03AK10
R03AK07
R03AK06
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
R03AL01

References

  1. Boehringer Ingelheim BV, SPC Combivent (RVG 20233), www.cbg-meb.nl, Geraadpleegd 12 aug 2010, http://db.cbg-meb.nl/IB-teksten/h20233.pdf
  2. NVK , Richtlijn Astma bij Kinderen, 2013

Changes

Therapeutic Drug Monitoring


Overdose